The company’s CFO Petr Sulc repeated in an interview for Reuters that Zentiva might buy back up to 10% of its shares. The possible buy-back was approved at the June AGM. Sulc said Zentiva might use the shares for future acquisitions as well as for the management option plan. Last week the press speculated that Zentiva is in negotiations to buy Romanian generic company Terapia. The company has just confirmed its interest in acquisitions in EU and in Eastern Europe, but did not indicate any specific project.